Navigation Links
DJO Incorporated's Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
Date:8/19/2007

r absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based on DJO's and ReAble's current expectations and are subject to a number of risks, uncertainties and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. The important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to, the occurrence of any event, change or other circumstance that could give rise to a termination of the merger agreement; the outcome of any legal proceedings that may be instituted against DJO, ReAble or others following the announcement of the merger agreement, the inability to complete the merger due to the failure to obtain stockholder approval or the failure to satisfy other conditions to the merger, including receiving applicable foreign regulatory approvals relating to the transaction; the failure to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the merger; risks that the proposed transaction disrupts current plans and operations and the potential difficulties in employee retention as a result of the merger. Other risk factors are detailed in the Company's Quarterly Report on Form 10-Q for the three months ended June 30, 2007, filed on August 3, 2007, with the Securities and Exchange Commission and ReAble's Quarterly Report on Form 10-Q for the three months ended June 30, 2007, filed on August 14, 2007, with the Securities and Exchange Commission. Many of the factors that will determine the outcome of the subject matter of this press release are beyond DJO's and ReAble's ability to control or predict.

DJO Investor/Media Contact:

DJO Incorporated

Mark Francois, Director of Investor Relations

(760) 734-4766


SOURCE ReAble Therapeutics Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Doyle urges support of higher education spending
2. Doyle outlines spending for Medical College, UWM
3. Chippewa Valley to get $46 million in defense spending
4. In public attitudes about taxes and spending, Wisconsin is Jekyll and Hyde
5. Audit of multi-million dollar state IT spending will proceed
6. Stratagene sets aside $21M to pay Third Wave pending appeal
7. New report says Wisconsin R&D spending exceeding expectations
8. IT Spending to Increase in Second Half of 2003
9. Technology and mergers: Getting the strategic applications
10. AT&T - BellSouth merger: Revestiture continues
11. CDW names VP to handle Berbee merger
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... The Latin American hardware encryption display market report ... analysis and forecast of revenue. This market was valued ... reach $2,366.8 million by 2018, at a CAGR of ... TOC of the Latin American hardware encryption market report ... It also provides a glimpse of the segmentation of ...
(Date:10/19/2014)... October 19, 2014 The Asia-Pacific Speech ... market in Asia-Pacific with analysis and forecast of revenue. ... in 2014 to $208 million by 2019, at a ... to 2019. , Browse through the TOC of the ... of the in-depth analysis provided. It also provides a ...
(Date:10/18/2014)... The “Human Insulin Market- by Product Type, ... Human Insulin (Rapid Acting, Long Acting, Premixed)], by ... - Forecast to 2018” provides a detailed overview ... market trends, and strategies impacting the global human ... of the revenue and share analysis. , The ...
(Date:10/18/2014)... The Asia-Pacific Liquid Crystal on Silicon (LCoS) ... in Asia-Pacific with analysis and forecast of revenue. This ... is expected to reach $380.0 million by 2018, at ... Browse through the TOC of the Asia-Pacific LCoS display ... analysis provided. This also provides a glimpse of the ...
Breaking Biology Technology:The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 2The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 3The Asia-Pacific Speech Analytics market is estimated to reach $208 million by 2019 - New Report by MicroMarket Monitor 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 2Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 3Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 4Medical Human Insulin Market Is Expected to Reach $42 billion by 2019 - New Research Report by MarketsandMarkets 5The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Liquid Crystal on Silicon (LCoS) display market is expected to reach $380.0 million by 2018 - New Report by MicroMarket Monitor 3
... ... Developers , ... March 4, 2010 -- This seminar details the fast-growing GenomeQuest sequence data management (SDM) platform ... discussion, and startup to Free Basic Account. , , ,When: March 17, 2010 ...
... , ... ... ... ...
... ... ... ... ...
Cached Biology Technology:GenomeQuest Hosting Seminar at X Gen Congress In San Diego 2GenomeQuest Hosting Seminar at X Gen Congress In San Diego 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 2Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 3Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 4Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 5Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 6Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 7Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 8Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 9Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 10Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 11Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 12Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 13Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 14Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 15Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 16Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 17Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 18Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 19Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 20Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 21Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 22Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 23Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 24Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 25Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 26Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 27Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 28Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 29Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 30Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 31Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 32Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009 33Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials 2
(Date:10/15/2014)... rapidly and to an unexpected extent. The outbreak does ... the virus shows a new disease dynamic in regions, ... reason, the German National Academy of Sciences Leopoldina, acatech ... the Union of the German Academies of Sciences and ... today. , In the statement the academies call for ...
(Date:10/15/2014)... Oct. 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market releases photos and video ... Square on Monday October 13 th . ... Tunnel and angel investor Mr. Chad A. Verdi ... of NXT-ID thanked his investors and employees "for their work and ...
(Date:10/15/2014)... Oct. 15, 2014   Neurotechnology , a ... the availability of the VeriLook Surveillance 3.0 ... provides real-time biometric face identification using live video ... cameras. The new version not only identifies faces ... from objects while they are moving through the ...
Breaking Biology News(10 mins):Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 2VeriLook Surveillance 3.0 SDK Identifies Faces and Moving Objects, Differentiates Pedestrians from Other Moving Objects in Video Surveillance Systems 3
... City & Toronto, January 6, 2013For individuals with agonizing pain, ... causes more pain. Adults and children whose pain gets worse ... based on research published in the January 6 on-line edition ... a molecular pathway by which morphine can increase pain, and ...
... SECURITY -- Thwarting threats . . . Many ... in Oak Ridge Jan. 8-12 for the inaugural Cyber Sciences ... Richard Clarke, author of "CYBER WAR: The Next Threat to ... the agenda are four plenary panels, 44 research talks and ...
... altering the way cancer is diagnosed and treated, but traditional ... the message delivered this week in a column appearing in ... JAMA ) by Scripps Clinic physicians Eric Topol, Kelly Bethel ... serves as chief academic officer of Scripps Health and director ...
Cached Biology News:The pain puzzle: Uncovering how morphine increases pain in some people 2The pain puzzle: Uncovering how morphine increases pain in some people 3January 2013 story tips from Oak Ridge National Laboratory 2Scripps physicians call for change in cancer tissue handling 2
... II RNA gel stain is a sensitive ... when bound to RNA and low background in ... formaldehyde/agarose or polyacrylamide gels using laser scanners or ... A 500 µL unit size (S-7564) and a ...
... Glutathion-S-Transferase-pi EIA Principle: ... enzymes, which are involved in the ... in 5 subgroups: Alpha, Mu, Pi, ... in their physiochemical, immunological, enzymatic and ...
... screening and binding optimization and built on ... synthesis platform. These microarrays are available as ... Service. Probe Content Our ... than 1500 known aptamer sequences. Add up ...
... comprehensive service for custom peptide microarray ... synthesized on Paraflo microfluidic chips for ... serum samples. This comprehensive service includes ... assays using sample(s) provided by you, ...
Biology Products: